Liminal BioSciences is a biopharmaceutical company dedicated to the discovery and development of innovative, small molecule drug candidates. With a focus on treating metabolic, fibrotic, and inflammatory diseases, they utilize a data-driven approach and a robust drug discovery platform. Their expertise in small molecules has led to the development of a strong product pipeline, encompassing potential first/best-in-class drug candidates.

These candidates have the potential to revolutionize the treatment landscape for a range of diseases. Investors can find more information about Liminal BioSciences' progress in developing these novel small molecule therapeutics. The company is listed on NASDAQ under the ticker symbol LMNL.

Liminal BioSciences is committed to making a positive impact on patient lives by providing effective treatments. Through their dedication, experienced management team, and cutting-edge research, they are driving innovation in the field of biopharmaceuticals. For the latest news and information, visitors can browse the resources hub on their website.

Liminal BioSciences is positioned as a leader in the field and is at the forefront of transforming healthcare through their groundbreaking drug discovery efforts